The study, conducted by multiple health centers in Italy, included 349 patients with a mean age of 79.9. Participants who complained of memory lapses, but showed no signs of brain damage or Alzheimer’s, were given 500mg of citicoline. Their memory was tested at three, six, and nine months, and then compared to tests given to a control group taking no supplements.
A “significant difference” was found between the study and control groups at both three and six months. Each group was given a series of questions called the Mini Mental State Examination (MMSE). Healthcare professionals use the MMSE common test to help diagnose and assess the progression and severity of memory problems. The control group MMSE scores declined significantly while the citicoline group remained at baseline. This significant difference is an indicator that citicoline has neuroprotective effects. Participants taking citicoline also reported no adverse side effects.
“In this study, citicoline was effective and well tolerated in patients with mild vascular cognitive impairment,” the study stated. “Citicoline activates biosynthesis of phospholipids in neuronal membranes, increases brain metabolism as well as norepinephrine and dopamine levels in the central nervous system, and has neuroprotective effects during hypoxia and ischemia.”
“Therefore, citicoline may be recommended for patients with mild vascular cognitive impairment,” the study concluded.
Other clinical trials have shown Cognizin Citicoline helps maintain normal cognitive function with aging, protects the brain from free radical damage, and is effective in combating certain neurodegenerative processes.
For more information: www.cognizin.com